Neurogene Inc. Files 8-K Report
Ticker: NGNE · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1404644
Sentiment: neutral
Topics: 8-K, regulatory-filing, company-information
Related Tickers: NGNE
TL;DR
Neurogene Inc. filed an 8-K, mostly procedural stuff and past name changes.
AI Summary
On June 18, 2024, Neurogene Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., Aquinox Pharmaceuticals, Inc., and Aquinox Pharmaceuticals (USA) Inc., with its most recent name change on August 12, 2019.
Why It Matters
This 8-K filing serves as a public record of Neurogene Inc.'s regulatory disclosures and financial exhibits, providing transparency to investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Neoleukin Therapeutics, Inc. (company) — Former company name
- Aquinox Pharmaceuticals, Inc. (company) — Former company name
- Aquinox Pharmaceuticals (USA) Inc. (company) — Former company name
- June 18, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing by Neurogene Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the most recent name change for Neurogene Inc.?
The most recent name change for Neurogene Inc. was on August 12, 2019, when it was formerly known as Neoleukin Therapeutics, Inc.
What is Neurogene Inc.'s principal executive office address?
Neurogene Inc.'s principal executive office is located at 535 W 24th Street, 5th Floor, New York, NY 10011.
What is the SIC code for Neurogene Inc.?
The Standard Industrial Classification (SIC) code for Neurogene Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What were the previous names of Neurogene Inc.?
Neurogene Inc. was previously known as Neoleukin Therapeutics, Inc., Aquinox Pharmaceuticals, Inc., and Aquinox Pharmaceuticals (USA) Inc.
Filing Stats: 599 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-06-18 14:11:01
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value NGNE The Nasdaq Global Market
Filing Documents
- ngne-20240618.htm (8-K) — 27KB
- irsfpr_final.htm (EX-99.1) — 17KB
- image_0.jpg (GRAPHIC) — 3KB
- 0001404644-24-000073.txt ( ) — 179KB
- ngne-20240618.xsd (EX-101.SCH) — 2KB
- ngne-20240618_lab.xml (EX-101.LAB) — 22KB
- ngne-20240618_pre.xml (EX-101.PRE) — 13KB
- ngne-20240618_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On June 18, 2024, Neurogene Inc. (the "Company") issued a press release announcing that the first patient in Cohort 2 of its Phase 1/2 clinical trial of NGN-401 gene therapy for Rett syndrome has received a high dose of the therapy and that the dose has been well tolerated to date. The Company also provided updated safety data on the three patients who have received the low dose of NGN-401 during the International Rett Syndrome Foundation ASCEND 2024 Rett Syndrome National Summit, which shows that NGN-401 continues to have an overall favorable safety profile with no new treatment-related adverse events. A copy of the press release announcing this presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated June 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NEUROGENE INC. Date: June 18, 2024 By: /s/ Christine Mikail Name: Christine Mikail Title: President, Chief Financial Officer